Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Hepatocellular Carcinoma
In pts with HCC who initially achieved a good response on durvalumab/tremelimumab , but later lost it, would you consider rechallenging with tremelimumab ?
Related Questions
What are your top takeaways from ASCO GI 2025?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
How would you approach the management of a patient with stage IIIA lung adenocarcinoma and multifocal hepatocellular carcinoma with Child-Pugh A cirrhosis?
What are your top takeaways in GI Cancers from ESMO 2024?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?
After neoadjuvant Nivolumab/Ipilimumab x4, do you offer adjuvant Nivolumab in the adjuvant setting for oligometastatic MSI-high colon cancer in a patient who achieved CR?
In a patient with metastatic colorectal cancer to the lung and liver, is there a role for liver directed therapy if the lung is not amenable to local therapy?
In a patient with a mid-esophageal squamous cell carcinoma with tracheal invasion confirmed on bronchoscopy, would you treat with definitive chemo-radiation with curative intent?
Do you always send for SDHB by IHC for workup of GIST? or is NGS/FISH that includes SDHB sufficient?
